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Background: Proteins secreted from the rhoptry in Plasmodium merozoites are associated with the formation of tight
junctions and parasitophorous vacuoles during invasion of erythrocytes and are sorted within the rhoptry neck or bulb.
Very little information has been obtained to date about Plasmodium vivax rhoptry-associated leucine (Leu) zipper-like
protein 1 (PvRALP1; PVX_096245), a putative rhoptry protein. PvRALP1 contains a signal peptide, a glycine (Gly)/glutamate
(Glu)-rich domain, and a Leu-rich domain, all of which are conserved in other Plasmodium species.
Methods: Recombinant PvRALP1s were expressed as full-length protein without the signal peptide (PvRALP1-Ecto) and
as truncated protein consisting of the Gly/Glu- and Leu-rich domains (PvRALP1-Tr) using the wheat germ cell-free
expression system. The immunoreactivity to these two fragments of recombinant PvRALP1 protein in serum samples
from P. vivax-infected patients and immunized mice, including analysis of immunoglobulin G (IgG) subclasses, was
evaluated by enzyme-linked immunosorbent assay or protein microarray technology. The subcellular localization of
PvRALP1 in blood stage parasites was also determined.
Results: Recombinant PvRALP1-Ecto and PvRALP1-Tr proteins were successfully expressed, and in serum samples from
P. vivax patients from the Republic of Korea, the observed immunoreactivities to these proteins had 58.9% and 55.4%
sensitivity and 95.0% and 92.5% specificity, respectively. The response to PvRALP1 in humans was predominantly
cytophilic antibodies (IgG1 and IgG3), but a balanced Th1/Th2 response was observed in mice. Unexpectedly, there was
no significant inverse correlation between levels of parasitaemia and levels of antibody against either PvRALP1-Ecto
(R2 = 0.11) or PvRALP1-Tr (R2 = 0.14) antigens. PvRALP1 was localized in the rhoptry neck of merozoites, and this was the
first demonstration of the localization of this protein in P. vivax.
Conclusions: This study analysed the antigenicity and immunogenicity of PvRALP1 and suggested that PvRALP1
may be immunogenic in humans during parasite infection and might play an important role during invasion of
P. vivax parasites.
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Malaria is a disease caused by plasmodial parasite infec-
tion of host erythrocytes. The blood stage of Plasmo-
dium causes the pathobiology of malaria by invasion and
subsequent modification of human erythrocytes. There-
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unless otherwise stated.malaria parasites has mainly focused on blood-stage
parasite antigens, especially those located on the surface
or in the apical organelles of the merozoite, such as rhop-
tries and micronemes [1]. In the case of Plasmodium
vivax, using serological assays, a number of blood-stage
proteins that are potential blood-stage vaccine candidates
were screened in our previous study [2]. The antigenicity,
immunogenicity, function, and subcellular localization of
these proteins including merozoite surface protein 1 para-
log (MSP1P) [3,4], Pv41 [5], PvMSP10 [6], Pv12 [7], and
RhopH2 [8] were also evaluated.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and Plasmodium species, actively invade host cells
through a moving junction (MJ) complex assembled at
the parasite–host cell interface [9]. Major apical orga-
nelle proteins are involved in this serial invasion process,
and the rhoptry neck protein RON complex together
with the micronemal protein AMA1 forms the MJ
[10,11]. However, some rhoptry proteins are released
during invasion and migrate to the lumen or membrane
of the nascent parasitophorous vacuole or the interior of
the host cell, rather than to the MJ [12].
The rhoptry-associated leucine (Leu) zipper-like pro-
tein 1 of Plasmodium falciparum (PfRALP1) was first
identified by a high degree of protein sequence homo-
logy among field isolates, and translocates from the
rhoptry neck to the MJ during merozoite invasion [13].
Attempts to knock out pfralp1 were unsuccessful [14],
which suggests that it might play an important role in
invasion of malaria parasites. Recently, an erythrocyte-
binding epitope in the C-terminal region of PfRALP1
was identified, it was shown that anti-RALP1 antibodies
disrupted MJ formation, and growth and invasion inhi-
bition assays confirmed the important role of PfRALP1
during merozoite invasion of erythrocytes [13]. Six
orthologs of PfRALP1 have been found in different
Plasmodium species [15]. Comparative analysis of the de-
duced amino acid sequences of the PfRALP1 and P. vivax
RALP1 (PvRALP1) revealed an overall sequence identity
of ~67% and similarity of ~83% [16]. Through liquid
chromatography-tandem mass spectrometry, PvRALP1
has been identified in clinical isolates [17,18] and the
VCG-1 strain, and in silico modelling predicted it as a
vaccine candidate [19]. All RALP1 orthologs include
coiled-coil region(s); these regions are targets for antibody
recognition and these antibodies may be possibly pro-
tective [20].
Profiling of PfRALP1 has shown its robust immuno-
genicity among blood-stage antigens of P. falciparum
[13,21]. As an ortholog of PfRALP1, PvRALP1 is also
likely to be immunogenic during malaria parasite infec-
tion in humans [16]. In this study, strong antigenicity
and immunogenicity of PvRALP1, and its localization
in the rhoptry neck of merozoites of P. vivax were
demonstrated.
Methods
Blood samples of Plasmodium vivax patients
A total of 112 blood samples (mean parasitaemia 0.117%,
range 0.002–0.630%) were obtained from patients who
were confirmed positive for P. vivax malaria via micros-
copy at Kangwon National University Hospital and at local
health centres and clinics in Gangwon Province, which is
a malaria-endemic area of the Republic of Korea. The
mean age of patients was 27 years (range 18–61 years).Eighty blood samples were also taken from healthy indi-
viduals in nonmalaria-endemic areas, who were confirmed
negative for P. vivax malaria by microscopy, and had no
previous history of malaria. This study was approved by
the Institutional Review Board at Kangwon National
University Hospital and all the blood samples were
collected after obtaining informed consent.
Enrichment of parasite-infected erythrocytes for parasite
antigen
Plasmodium vivax-infected blood samples were collected
from patients and parasite-infected erythrocytes were puri-
fied as reported previously [22]. White blood cells were re-
moved from infected patient samples using a Plasmodipur
filter (Euro-Diagnostica, Arnhem, The Netherlands), and
the erythrocytes resuspended in RPMI-1640 medium
(Invitrogen, Carlsbad, CA, USA) to make a 10% haemato-
crit suspension. Thereafter, schizont-rich infected erythro-
cytes were enriched by 60% Percoll gradient centrifugation
and used as a source of parasite antigens for western blot
and immunofluorescence analyses.
Expression and purification of recombinant PvRALP1
proteins
Genomic DNA was prepared from Korean isolates of
P. vivax as described previously [16]. The full-length of
pvralp1 comprising amino acid 1 to 675 was amplified
from genomic DNA with the forward primer RALP1-F:
5′-ATGAAGCGGAGCATCGC-3′ and reverse primer
RALP1-R: 5′-CTAGAACATGTCGTAGAGCAGGC-3′.
The PCR amplification was performed on a MyCycler
Thermal Cycler (Bio-Rad, Hercules, CA, USA) using the
following temperature profile: 95°C for 4 min; 30 cycles
at 95°C for 30 sec, 53°C for 30 sec, 72°C for 2 min; and a
final extension at 72°C for 10 min. The resulting PCR
product was cloned into the pCR2.1 TOPO vector
(Invitrogen). Automated DNA sequence analysis of the
cloned vector was performed using an ABI Prism 3730XL
DNA Sequencer (Applied Biosystems, Foster City, CA,
USA). The predicted protein domains of PvRALP1 were
further analysed using the Simple Modular Architecture
Research Tool (SMART) [23] and SOSUIsignal [24].
To express the two recombinant PvRALP1 proteins, the
open reading frame of pvralp1 without the signal peptide
sequence (pvralp1-ecto; comprising amino acids 31 to 675)
was amplified with the forward primer RALP1-Ecto
F: 5′-atcactagttctcgagATGGCGTACCGCCTAAAGAGG-3′
and the reverse primer RALP1-Ecto R: 5′-ccctatatat
ggatccTCACTAGAACATGTCGTAGAGCAGGC-3′, and
the truncated pvralp1 (pvralp1-tr; comprising amino
acids 257 to 503) with a hexa-histidine (His)-tag at the
C-terminus was amplified with the forward primer
RALP1-Tr-F: 5′-atcactagttctcgagATGACCTACGCGAGC
TACGAAC-3′ and reverse primer RALP1-Tr-R: 5′-
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TTAGCAAATTAGAGACGATGTTCTG-3′. The vector
sequences are shown in lowercase, and the restriction
enzyme sites (XhoI for sense primers and BamHI for anti-
sense primers) in italics. The underlined sequences in the
antisense primers above indicate the regions that encode
the His-tag. The amplified DNA sequences of pvralp1-ecto
and pvralp1-tr were cloned into the XhoI and BamHI sites
of the pEU-E01-GST-TEV-MCS-N2 and pEU-E01-MCS
vectors (CellFree Sciences, Matsuyama, Japan), respec-
tively. Plasmid DNA was then prepared using the Maxi
Plus™ Ultrapure plasmid extraction system (Viogene,
Taipei, Taiwan) according to the manufacturer’s instruc-
tions. Purified plasmid DNA was eluted in 0.1× TE buffer
(10 mM Tris–HCl, pH 8.0, 1 mM EDTA) and used for
in vitro transcription for recombinant protein expression
in the wheat germ cell-free (WGCF) system (CellFree
Sciences). Glutathione S-transferase (GST) fusion PvRALP1-
Ecto protein was purified with a glutathione-Sepharose 4B
column according to the manufacturer’s instructions
(GE Healthcare, Camarillo, CA, USA). PvRALP1-Tr pro-
tein with a His-tag at the C-terminus was purified using
nickel nitrile-triacetic acid (Ni-NTA) affinity chromato-
graphy as described elsewhere [25].
Immunization of mice and rabbit with recombinant
PvRALP1s
To generate antibodies against PvRALP1-Ecto or PvRALP-
Tr, three BALB/c mice for each protein were immunized
subcutaneously with 20 μg per mouse of purified protein
in Freund’s complete adjuvant, followed by two injections
of 20 μg in Freund’s incomplete adjuvant three weeks and
six weeks later. In addition, one Japanese white rabbit
was immunized subcutaneously with 250 μg of purified
PvRALP1-Tr in Freund’s complete adjuvant, followed by
two injections of 250 μg in Freund’s incomplete adjuvant
three weeks and six weeks later. The antisera were col-
lected 14 days after the last immunization. Animal expe-
rimental protocols were approved by the Institutional
Animal Care and Use Committee of Ehime University and
Kangwon National University, and the experiments were
conducted according to the Ethical Guidelines for Animal
Experiments of Ehime University and Kangwon National
University.
SDS-PAGE and western blot analysis
The parasite proteins were extracted in reducing sample
buffer for SDS-PAGE. Five micrograms of recombinant
PvRALP1-Ecto or PvRALP1-Tr protein were loaded into
each well and separated by SDS-PAGE under reducing
conditions. The separated proteins were transferred to
0.45 μm polyvinylidene fluoride membranes (Millipore,
Billerica, MA, USA) in a semidry transfer buffer (50 mM
Tris, 190 mM glycine, 3.5 mM SDS, 20% methanol) at400 mA for 40 min using a semidry blotting system
(ATTO Corp., Tokyo, Japan). After blocking with 5%
skim milk in phosphate-buffered saline containing 0.2%
Tween 20 (PBS-T), the membranes were probed with
mouse anti-PvRALP1-Ecto and anti-PvRALP1-Tr sera,
rabbit anti-PvRALP1-Tr serum, anti-GST monoclonal
antibody (Novagen, Madison, WI, USA), anti-penta-His
monoclonal antibody (Qiagen), preimmune mouse serum,
pooled sera from P. vivax malaria patients or noninfected
individuals, all diluted 1:200 in PBS-T. IRDye goat anti-
mouse, IRDye goat anti-rabbit, or IRDye goat anti-human
sera (LI-COR Biosciences, Lincoln, NE, USA) were used
to detect recombinant proteins according to the manufac-
turer’s instructions. Data were scanned with an Odyssey
infrared imaging system (LI-COR Biosciences) and ana-
lysed with Odyssey software (LI-COR Biosciences).
Serum screening using protein arrays
Sera from 112 patients with P. vivax malaria and 80 healthy
individuals were tested against the recombinant PvRALP1-
Ecto and PvRALP1-Tr proteins using protein arrays. A
series of doubling dilutions was used to optimize the coat-
ing antigen concentration (3 to 200 ng/μL) of each recom-
binant protein. As a result, one microlitre of 50 ng/μL
recombinant PvRALP1-Ecto or PvRALP1-Tr proteins
were spotted onto each well of an amino-functionalized
slide and incubated for 2 h at 37°C. The arrays were first
blocked with 5% bovine serum albumin in PBS-T for 1 h
at 37°C, then they were probed with human serum (1:10)
that was preabsorbed against wheat germ lysate (1:100) to
remove anti-wheat germ antibodies. The arrays were incu-
bated with serum in PBS-T for 1 h at 37°C and antibodies
were visualized with 10 ng/μL Alexa Fluor 546 goat anti-
human immunoglobulin G (IgG; Invitrogen) diluted in
PBS-T, and scanned in a fluorescence scanner (ScanArray
Express; PerkinElmer, Boston, MA, USA) [7]. Fluores-
cence intensities of array spots were quantified by the
fixed-circle method using ScanArray Express software
(version 4.0; PerkinElmer). The positive cutoff value was
calculated as the mean fluorescence intensity (MFI) of the
negative controls plus 2 standard deviations (SD).
To investigate the human IgG subclasses comprising the
response against PvRALP1-Ecto and PvRALP1-Tr, sera
from fifty P. vivax-positive patients from malaria-endemic
areas and ten P. vivax-negative sera from malaria nonen-
demic areas of Korea were randomly selected. One mi-
crolitre of 50 ng/mL PvRALP1-Ecto and PvRALP1-Tr
proteins were spotted onto each well and incubated for
2 h at 37°C. After blocking, plasma was added in duplicate
at previously determined dilutions. For measurement of
IgG subclasses, mouse monoclonal antibodies to human
IgG subclasses (IgG1, clone HP6096, IgG2 clone HP6002,
IgG3 clone HP6047, and IgG4 clone HP6025 [Invitrogen])
as secondary antibodies were added at a dilution of
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(Invitrogen) was added at 50 ng/μL as the tertiary anti-
body for the subclass assays. Finally, the data from
scanned images were analysed as above.Enzyme-linked immunosorbent assay (ELISA)
To compare the IgG subclasses in anti-PvRALP1 and
anti-PvRALP1-Tr immune mouse sera, PvRALP1-Ecto
(5 μg/mL) or PvRALP1-Tr (5 μg/mL) was coated on 96-
well ELISA plates. One hundred microlitres of purified
mouse IgG1, IgG2a, IgG2b, and IgG3 (BD Pharmingen
Corp., San Diego, CA, USA) as standards were also coated
on 96-well plates at 256, 128, 64, 32, 16, 8, and 4 ng/mL.
The coated plates were incubated with immune mouse
sera diluted 1:1,000 in PBS-T. After washing, the plates
were incubated with horseradish peroxidase-conjugated
anti-mouse IgG1, IgG2a, IgG2b, and IgG3 antibodies
(Invitrogen) at 1:1,000, 1:1,000, 1:2,000, and 1:1,000 dilu-
tions, respectively. After washing, the plates were incu-
bated with 100 μL of tetramethylbenzidine solution and
the absorbance at 450 nm was measured within 1 h after
addition of the stop solution. The concentration of each
IgG subclass was calculated using a log − log curve fit.Indirect immunofluorescence assay (IFA)
IFAs were performed on acetone-fixed parasites as de-
scribed previously [7]. The following primary antibody
dilutions were used: mouse anti-PvRALP1-Tr (1:50),
rabbit anti-PvRON2 (1:100), rabbit anti-PvDBP (1:100),
and rabbit anti-PvRhopH2 (1:100). The following se-
condary antibodies were used: Alexa Fluor 488 goat
anti-mouse IgG (1:500; Invitrogen), Alexa Fluor 546 goat
anti-rabbit IgG (1:500; Invitrogen) and 4′,6′-diamidino-
2-phenylindole (DAPI) for nuclear staining (1:1,000;
Invitrogen). The slides were mounted in ProLong Gold
antifade reagent (Invitrogen) and visualized under oil
immersion in a confocal scanning laser microscope
(LSM710; Carl Zeiss MicroImaging, Thornwood, NY,
USA) using a Plan-Apochromat 63×/1.4 oil differential
interference contrast (DIC) objective lens. Images were
captured with Zen software (Carl Zeiss MicroImaging)
and processed with Adobe Photoshop (Adobe Systems,
San Jose, CA, USA).Statistical analyses
Simple scatter regression was used to construct a standard
curve using SigmaPlot (Systat Software Inc., San Jose,
CA, USA). Data were analysed using GraphPad Prism
(GraphPad Software, San Diego, CA, USA); Student’s t-test
or one-way ANOVA was used to evaluate the differences
between the means of each group. Differences with p < 0.05
were considered significant.Results
Pvralp1 gene structure
The gene sequence and transcription profiles of pvralp1
(PlasmoDB accession no. PVX_096245) have been de-
posited at the PlasmoDB Web site [26]. Because of the
lack of information about whether PvRALP1 contained a
signal peptide, the pfralp1 ortholog in P. vivax was
amplified from 169 base pairs (bp) upstream of the
N-terminal of PVX_096245 and analysed. A putative
signal peptide encoded in the 5′ upstream section of the
pvralp1 gene sequence was found. Hence, to obtain the
full-length pvralp1 gene sequence, the full-length target
gene from 169 bp upstream of PVX_096245 was ampli-
fied and sequenced, and the full-length PvRALP1 pro-
tein sequence comprising 675 amino acid (aa) residues
was successfully annotated. In detail, the full-length
PvRALP1 contains a signal peptide (aa 1–23), a Gly- and
glutamate (Glu)-rich region (aa 301–387), and a Leu-rich
region (aa 431–452) (Figure 1A). A Leu zipper domain
[L431-(X)6-L-(X)6-L(X)6-L452] similar to that of PfRALP1,
could not be predicted by the 2ZIP server [27] (Figure 1A).
One coiled-coil α-helical motif (aa 517–546), which might
be involved in protein–protein interactions, was identified
(Figure 1A), and was characterized by heptamino acid
repeats (abcdefg)n with hydrophobic residues located in
positions a and d, and generally polar residues in the
remaining sites.
Expression of recombinant PvRALP1-Ecto and PvRALP1-Tr
proteins using the WGCF system
To characterize the PvRALP1 protein and its particular
structure, including the Gly/Glu-rich and Leu-rich do-
mains, PvRALP1-Ecto (without signal peptide, aa 31–675)
protein with a GST-tag and PvRALP1-Tr (aa 257–503)
protein with a His-tag (Figure 1A) were expressed using
the WGCF system. The recombinant PvRALP1-Ecto and
PvRALP1-Tr proteins were expressed in the soluble frac-
tion (Figure 1B and C; arrows) and purified by affinity
chromatography. Although there was expression of other
proteins in the crude lysate, causing the corresponding
weak bands in the T, S, E1, and E2 lanes, the purified tar-
get proteins are clearly visible in lanes E3. These results
demonstrated that the WGCF system is able to produce
PvRALP1-Ecto and PvRALP1-Tr as soluble proteins.
Recognition of recombinant PvRALP1 proteins
Recombinant PvRALP1-Ecto and PvRALP1-Tr proteins
were used to immunize mice or a rabbit to produce
polyclonal antibodies. Immune sera from these animals
and those from P. vivax-infected humans specifically
recognized PvRALP1-Ecto and PvRALP1-Tr (Figure 2A).
However, neither preimmune animal sera nor sera from
noninfected humans reacted with these antigens, sug-
gesting that PvRALP1 induced specific responses in both
Figure 1 Schematic diagram and protein expression of PvRALP1-Ecto and PvRALP1-Tr. (A) Schematic diagram of PvRALP1-Ecto and the central
domain comprising PvRALP1-Tr. (B) Expression and purification of recombinant PvRALP1-Ecto and (C) PvRALP1-Tr fragments. Arrowheads indicate
specific bands for each recombinant protein. M, protein marker; T, total translation mix; S: supernatant; P, pellet; Ft: flow through; E1, elution
fraction 1; E2, elution fraction 2; E3, elution fraction 3.
Figure 2 Western blot analysis of recombinant PvRALP1-Ecto, PvRALP1-Tr, and schizont lysate probed with antisera to PvRALP1-Ecto and PvRALP1-Tr,
and sera from P. vivax malaria patients and healthy controls. (A) PvRALP1-Ecto and PvRALP1-Tr were probed respectively with anti-GST antibody (Gst),
immune mouse sera (M), pooled P. vivax patient sera (P), anti-His antibody (His), immune rabbit sera (R), nonimmune mouse sera (N), and sera from
noninfected humans (H). (B) Recognition of PvRALP1 antigen in the parasite lysate with mouse (1) and rabbit (2) antisera against PvRALP1-Tr,
preimmune mouse sera (3), and preimmune rabbit serum (4), respectively. Arrowheads indicate the target bands for native and recombinant
proteins and putative processed fragments. The asterisk indicates a nonspecific band present in each lane.
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Figure 3 Total IgG antibody responses to PvRALP1-Ecto and PvRALP1-Tr assessed protein microarrays. Immunoreactivity of total IgG against each
antigen was determined with the sera of malaria patients (Patients) and healthy individuals (Healthy) from the Republic of Korea. High specificity
of responses and significant differences between P. vivax patients and healthy individuals were observed in the prevalence of total IgG specific
for the two PvRALP1 antigens (p < 0.0001).
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recognized native PvRALP1 from the parasite, P. vivax
schizont-enriched lysate was tested against mouse and
rabbit anti-PvRALP1-Tr antibodies. Both anti-PvRALP1-Tr
antisera (Figure 2B, lanes 1, 2; arrowheads) but not preim-
mune sera (Figure 2B, lanes 3, 4) recognized a band ap-
proximately 73 kDa in size. A nonspecific 12 kDa band
(Figure 2B, lanes 3, 4, asterisk) from erythrocyte ghosts
was detected by both antisera and preimmune sera.
Analysis of humoral immune responses
To further evaluate the humoral immune responses against
PvRALP1-Ecto and PvRALP1-Tr, the antibody responses
against these targets in serum samples from 112 patients
infected with P. vivax and 80 healthy individuals were de-
termined. The sera from P. vivax-exposed individuals
showed significantly higher MFI than those from malaria-
naïve subjects (Figure 3, p < 0.0001). The prevalenceTable 1 Prevalence (% positive), 95% confidence intervals, an
Plasmodium vivax RALP1-Ecto and RALP1-Tr in sera from hum
RALP1 No. of patient samples (n) 95% CIb MFI (%) N
Positive Negative Total (%)a Po
Ecto 66 46 112 (58.9) 49.67–67.6 14138 4
Tr 62 50 112 (55.4) 46.13–64.23 8757 6
MFI = mean fluorescence intensity.
aSensitivity: % positive in patient samples.
bConfidence intervals.
cSpecificity: % negative control healthy samples.
dDifferences in the total IgG prevalence for each antigen between P. vivax patients
considered significant.of anti-PvRALP1-Ecto and anti-PvRALP1-Tr antibodies
showed that the sensitivities were 58.9% and 55.4% and the
specificities were 95.0% and 92.5%, respectively (Table 1).
To clarify whether anti-PvRALP1 antibody levels cor-
relate with effective immunity, the antibody responses
against the two antigens were analysed in association
with the individual levels of parasitaemia in 56 patients
(Figure 4A and B). There was no significant inverse cor-
relation between levels of parasitaemia and levels of
antibody against either PvRALP1-Ecto (R2 = 0.11) or
PvRALP1-Tr (R2 = 0.14) antigen. However, there were no
patients with high antibody levels who also had high para-
sitaemia (Figure 4A and B, top right quadrant).
Isotype distribution of the IgG response to PvRALP1
antigen in malaria patients and immunized mice
Because protective antibodies against Plasmodium blood
stages have been shown to belong to the cytophilicd mean fluorescence intensity of IgG responses to
an P. vivax patients and healthy individuals
o. of healthy individuals (n) 95% CI MFI (%) P-valued
sitive Negative Total (%)c
76 80 (5.0) 87.54–97.99 5032 p < 0.0001
74 80 (7.5) 84.59–96.52 3047 p < 0.0001
and healthy individuals were calculated with Student’s t-test. P < 0.05 was
Figure 4 Correlation between peripheral blood parasitaemia in P. vivax patients and the immunoreactive fluorescence intensity of their sera.
Correlation between immunoreactivity of total IgG against PvRALP1-Ecto (A) and PvRALP1-Tr (B) and the parasitaemia of each P. vivax patient
sample was analysed for 56 P. vivax patient samples. R2 was calculated by a polynomial program.
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Ecto and RALP1-Tr antigens were analyzed. The mean
levels of the IgG subclasses in the responses of humans
to both antigens were ranked IgG3 > IgG2 > IgG1 > IgG4
(Figure 5), with no significant differences between the
subclasses (p > 0.05). However, the levels of all IgG sub-
classes for PvRALP1-Ecto were significantly higher than
those for PvRALP1-Tr (IgG1, p < 0.01; IgG2, p < 0.001;
IgG3, p < 0.05; and IgG4, p < 0.001). A balanced Th1/Th2
response was observed in mice immunized with PvRALP1-
Ecto and PvRALP1-Tr (IgG1/IgG2a ratios: 0.7 and 1.2).
As shown in Figure 6A and B, IgG2b levels (mean con-
centration 805.0 μg/mL) were found to be highest inFigure 5 IgG subclass antibody responses to PvRALP1-Ecto and PvRALP1-T
Student’s t-test. The bar indicates the mean ± standard deviation. MFI, mea
0.0001 < p < 0.01; triple asterisks, p < 0.0001.PvRALP1-Ecto-immunized mice and IgG1 levels (mean
concentration 490.5 μg/mL) were highest in PvRALP1-Tr-
immunized mice.
Localization of PvRALP1 in the rhoptry neck of the
merozoite
To determine the localization of the native PvRALP1
protein in merozoites of P. vivax, IFA was carried out on
mature schizont stage P. vivax using anti-PvRALP1-Tr;
anti-Duffy binding protein (DBP) as a microneme mar-
ker [29], anti-PvRhopH2 as a rhoptry body marker [8],
and anti-PvRON2 as a rhoptry neck marker [30]. The
IFA results showed that the apical distribution ofr assessed protein microarrays. The p values were calculated using
n fluorescence intensity. Single asterisk, 0.01 < p < 0.05; double asterisks,
Figure 6 PvRALP1-specific IgG subclass levels and percentages in
immune mouse sera. (A) IgG1 (black), IgG2a (white), IgG2b (dark
gray), and IgG3 (light gray) levels after the final immunizations
against PvRALP1-Ecto and PvRALP1-Tr were determined by ELISA.
(B) Geometric mean concentrations were calculated for each of the
four subclasses in each group of three mice and are presented as
percentages of the total IgG responses in BALB/c mice. The results
are expressed as mean titers ± SD. The p values, calculated using
Student’s t-test, indicate the number of sera analysed. Double asterisks,
0.0001 < p < 0.01; triple asterisks, p < 0.0001.
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clearly co-localized with that of PvRON2 (Figure 7A),
but not with that of PvDBP (Figure 7B) or PvRhopH2
(Figure 7C). These results demonstrate for the first time
that native PvRALP1 localizes in the rhoptry neck of
merozoites, although immunoelectron microscopic ob-
servation is essential to confirm this.
Discussion
In P. falciparum, anti-RALP1 antibodies inhibited the
merozoite invasion of erythrocytes and disrupted MJ for-
mation, which suggested that PfRALP1 is essential for
erythrocyte invasion [13]. PfRALP1 localized in the
rhoptry neck of the merozoite, and it translocated fromthe rhoptry neck to the MJ during merozoite invasion
[13]. In P. vivax parasites, because of the difficulty of
in vitro culture, the function of the analog is not easy to ex-
plore. However, the immune responses to and localization
of PvRALP1 could be analysed in this study. The rhoptry
neck localization of PvRALP1 in merozoites and its im-
mune profiling in P. vivax malaria patients suggested that
PvRALP1 may play a similar important role during the
merozoite invasion process to that of PfRALP1 [14].
In a previous study, the Glu-rich region of some Plas-
modium parasite proteins appeared to react strongly with
human IgG antibodies [31,32]. The α-helical coiled-coil
motifs were also targets of antibody recognition, sug-
gesting that these antibodies may be protective against
malaria vaccine candidates including liver stage antigen
(LSA)-1 [33], LSA-3 [34], MSP-3 [35], MSP-6 [36], and
MSP-1 [37]; such motifs have been used for rapid identifi-
cation of malaria vaccine candidates [20]. Because of its
structural similarity to PfRALP1, the immunogenicity
of PvRALP1 was characterized by immune profiling of
PvRALP1-Ecto and PvRALP1-Tr constructs including the
Gly/Glu-rich and Leu-rich domains. Although there were
no significant differences detected in either sensitivity or
specificity of responses in sera from infected humans to
each protein (Table 1), the intensity of IgG and IgG sub-
class responses to PvRALP1-Ecto were higher than those
against PvRALP1-Tr, which indicates that motifs including
a Gly/Glu-rich domain, a Leu-rich domain, and a coiled-
coil region may be related to the immunogenicity of these
proteins in infected patients.
A number of pvralp1 genomic sequences from 170 iso-
lates obtained worldwide are available in the PlasmoDB
databases and analysis for alignments showed a com-
paratively conserved pvralp1 gene. In addition, the total
number of single-nucleotide polymorphisms (SNPs) in all
P. vivax strains is 78, and the ratio of nonsynonymous/
synonymous SNPs ratio is 2.12 (53/25). A small number
of SNPs were detected that might be related to the low
antibody response against the two recombinant PvRALP
proteins that was observed in some patients’ sera.
Knowledge of the IgG subclass responses that are asso-
ciated with protection against malaria is essential for un-
derstanding anti-malaria immunity and guiding vaccine
research. IgG1 and IgG3 are the predominant subclasses
produced in response to merozoite antigens in humans
[38-41]. IgG1 and IgG3 are cytophilic and mediate phago-
cyte activation and complement fixation [42]. It has been
suggested that IgG3 is more efficient at mediating these
processes [42]. In the present study, both PvRALP1-Ecto
and PvRALP1-Tr induced predominantly IgG3 antibodies
(Figure 5), suggesting that PvRALP1 might induced func-
tional antibodies. While the factors determining subclass
responses to antigens are not clearly defined, antigen
properties, host age, cumulative exposure, and genetic
Figure 7 Subcellular localization of PvRALP1 protein in asexual blood-stage parasites of P. vivax. Acetone-fixed mature schizonts of P. vivax were
dual labeled with mouse immune sera against PvRALP1-Tr (green), PvRON2 (rhoptry neck marker) (A, red), rabbit immune sera against PvDBP
(microneme marker) (B, red), and PvRhopH2 (rhoptry marker) (C, red). Nuclei are visualized with DAPI (blue). DIC; differential interference contrast
image. Scale bar represents 5 μm.
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responses [43-45].
The IgG subclass responses to these two antigens in
immunized mice were evaluated, presuming that the
noncytophilic IgG1 and IgG3 isotypes correspond to a
Th2 response, whereas the cytophilic IgG2a and IgG2b
correspond to a Th1 response [46]. The results showed
that a balanced Th1/Th2 response was observed to both
antigens, and that IgG1 and IgG2b responses were
higher (Figure 6) in PvRALP1-immunized mice than any
of the other IgG subclasses. A similar IgG subclass dis-
tribution has been found in responses in mice immu-
nized with the vaccine candidate PfMSP3 [47], and these
were able to inhibit parasite growth. An erythrocyte
binding motif PvMSP1P-19 also induced predominantly
IgG2b responses in immunized mice [3]. It has been re-
ported that the function of mouse IgG2b is similar to
that of IgG3 in humans [48], and immunoepidemiolo-
gical studies have shown a significant correlation of hu-
man IgG3 antibody responses with protection acquired by
natural exposure to the parasite [49]. There was nosignificant inverse correlation between the level of parasit-
aemia and antibody levels against either PvRALP1-Ecto or
PvRALP1-Tr antigens, although there was also no patient
with high antibody levels and high parasitaemia (Figure 4).
These findings suggest that the level of anti-PvRALP1
antibodies does not strongly contribute to the degree of
inhibition of parasite growth. Furthermore, the levels of
IgG2b in PvRALP1-Ecto-immunized mice were paralleled
the levels of human IgG3 in sera from P. vivax-infected
patients (Figures 5 and 6).
In the present study, PvRALP1 localized to the rhop-
try neck of merozoite parasites was observed (Figure 7):
PvRALP1 completely colocalized with the rhoptry neck
marker PvRON2. Hence, we have clearly demonstrated
that PvRALP1 is likely to be a rhoptry neck protein of
P. vivax merozoites, although an immunoelectron mi-
croscopy study should be performed to confirm this.
During the invasion of the merozoite, rhoptry neck pro-
teins (i.e., RON2, RON4, RON5, and RON8) are dis-
charged from the rhoptries to form the MJ complex
with a microneme protein, AMA1, and this complex
Cheng et al. Malaria Journal  (2015) 14:186 Page 10 of 11plays an important role in the invasion of erythrocytes
[50]. Thus, it is possible that, like other rhoptry neck
proteins, PvRALP1 may also play an essential role in
this invasion process.
Conclusions
An investigation of immune responses to PvRALP1 and
investigation of its localization suggested that PvRALP1
might play an important role in erythrocyte invasion by
blood-stage Plasmodium vivax parasites. However, more
functional and biological investigations of PvRALP1 are
required.
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